1. Brandi, M.L., Multiple endocrine neoplasia type I: general features and new insights into etiology. J Endocrinol Invest, 1991. 14: p. 61.

2. Eberle, F. and R. Grun, Multiple endocrine neoplasia type I (MEN I). Ergeb Inn Med Kinderheilkd, 1981. 46: p. 76.

3. Thakker, R.V. and B.A. Ponder, Multiple endocrine neoplasia. Baillieres Clin Endocrinol Metab, 1988. 2: p. 1031.

4. Oberg, K., B. Skogseid, and B. Eriksson, Multiple endocrineneoplasia type I (MEN-1): clinical, biochemical and genetical investigations. Acta Oncol, 1989. 28: p. 383.

5. Samaan, N.A., S. Ouais, N.G. Ordonez, et. al., Multiple endocrine syndrome type I. Clinical, laboratory findings, and management in five families. Cancer, 1989. 64: p. 741.

6. Asgharian, B., M.L. Turner, F. Gibril, L.K. Entsuah, J. Serrano, and R.T. Jensen, Cutaneous tumors in patients with multiple endocrine neoplasm type 1 (MEN1) and gastrinomas: prospective study of frequency and development of criteria with high sensitivity and specificity for MEN1. J Clin Endocrinol Metab, 2004. 89(11): p. 5328-36.

7. Benya, R.V. and D.C. Metz, Zollinger-Ellison syndrome can be the inital endocrine manifestation in patients with multiple endocrine neoplasia-type I. Am J Med, 1994. 97: p. 436.

8. Skogseid, B. and J. Rastad, Multiple endocrine neoplasia type I. Endocrinol Metab Clin North Am, 1994. 23: p. 1.

9. Gibril, F., M. Schumann, A. Pace, and R.T. Jensen, Multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: a prospective study of 107 cases and comparison with 1009 cases from the literature. Medicine, 2004. 83(1): p. 43-83.

10. Eriksson, B., B. Skogseid, G. Lundqvist, et al., Medical treatment and long-term survival in a prospective study of 84 patients with endocrine pancreatic tumors. Cancer, 1990. 65: p. 1883.

11. Friesen, S.R., The development of endocrinopathies in the prospective screening of two families with MEA-I. World J Surg, 1979. 3: p. 753.

12. Lamers, C.B., J.T. Buis, and J.H.V. Tongeren, Secretin-stimulated serum gastrin levels in hyperparathyroid patients from families with multiple endocrine adenomatosis-type 1. Ann Intern Med, 1977. 86: p. 719.

13. Thompson, N.W., R.V. Lloyd, R.H. Nishiyama, et. al., MEN I pancreas: a histological and immunohistochemical study. World J Surg, 1984. 8: p. 561.

14. Howard, T.J. and E. Passaro, Jr., Gastrinoma: new medical and surgical approaches. Surg Clin North Am, 1989. 69: p. 667.

15. Pipeleers-Marichal, M., G. Somers, G. Willems, et al., Gastrinomas in the duodenums of patients with multiple endocrine neoplasia type I and Zollinger-Ellison syndrome. N Engl J Med, 1990. 332: p. 723.

16. Wynick, D., S.J. Williams, and S.R. Bloom, Symptomatic secondary hormone syndromes in patients with established malagnant pancreatic endocrine tumors. N Engl J Med, 1988. 319: p. 605.

17. Doherty, G.M., Multiple endocrine noeplasia type 1: duodenopancreatic tumors. Surgical Oncology, 2003. 12: p. 135-143.

18. Anlauf, M., A. Perren, C.L. Meyer, S. Schmid, P. Saremaslani, M.L. Kruse, E. Weihe, P. Komminoth, and G. Kloppel, Precursor lesions in patients with multiple endocrine neoplasia type 1 - associated duodenal gastrinomas. Gastroenterology, 2005. 158(5): p. 1187-98.

19. van Heerden, J.A., S.L. Smith, and L.J. Miller, The management of Zollinger-Ellison syndrome in patients with multiple endocrine neoplasm Type 1. Surgery, 1986. 100: p. 971-977.

20. Norton, J.A., Doppman J.L., Collen M.J. et.al., Prospective study of gastrinoma localization and resection in patients with Zollinger-Ellison syndrome. Ann Surg, 1986. 204: p. 468.

21. McCutcheon, I.E., Management of individual tumor syndromes: pituitary neoplasia. Endocrinol Metab Clin North Am, 1994. 23: p. 37.

22. Ballard, H.S., B. Frame, and R.J. Harstock, Familial multiple endocrine adenoma-peptic ulcer complex. Medicine, 1964. 43: p. 481.

23. Maton, P.M., J.D. Gardner, and R.T. Jensen, The incidence and etiology of Cushing's syndrome in patients with Zollinger-Ellison syndrome. N Engl J Med, 1986. 315: p. 1.

24. Schimke, R.N., Multiple endocrine neoplasia: how many syndromes? Am J Med, 1990. 37: p. 375.

25. Farhangi, M., J. Taylor, A. Havey, and T.M. O'Dorisio, Neuroendocrine (carcinoid) tumor of the lung and type I multiple endocrine neoplasia. South Med J, 1987. 80: p. 1459.

26. Cadiot, G. and P.P. Laurent, Is the multiple endocrine neoplasia type I gene a suppressor for fundic argyrophil tumors in the Zollinger-Ellison syndrome? Gastroenterology, 1993. 105: p. 579.

27. Larsson, C., B. Skogseid, K. Oberg, Y. Nakamura, and M. Nordenskjold, Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma. Nature, 1988. 332(6159): p. 85-7.

28. The European Consortium on MEN1. Linkage disequilibrium studies in multiple endocrine neoplasia type 1 (MEN1). Hum Genet, 1997. 100(5-6): p. 657-65.

29. Chandrasekharappa, S.C., S.C. Guru, P. Manickam, S.E. Olufemi, F.S. Collins, M.R. Emmert-Buck, L.V. Debelenko, Z. Zhuang, I.A. Lubensky, L.A. Liotta, J.S. Crabtree, Y. Wang, B.A. Roe, J. Weisemann, M.S. Boguski, S.K. Agarwal, M.B. Kester, Y.S. Kim, C. Heppner, Q. Dong, A.M. Spiegel, A.L. Burns, and S.J. Marx, Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science, 1997. 276(5311): p. 404-7.

30. Calender, A., Molecular genetics of neuroendocrine tumors. Digestion, 2000. 62(suppl 1): p. 3-18.

31. Mutch, M.G., W.G. Dilley, F. Sanjurjo, D. M.K., G.M. Doherty, S.A. Wells, Jr., P.J. Goodfellow, and T.C. Larimore, Germline Mutations in the multiple endocrine neoplasia type 1 gene: evidence for the frequent splicing defects. Human Mutation, 1999. 13: p. 175-85.

32. Agarwal, S.K., A. Lee Burns, K.E. Sukhodolets, P.A. Kennedy, V.H. Obungu, A.B. Hickman, M.E. Mullendore, I. Whitten, M.C. Skarulis, W.F. Simonds, C. Mateo, J.S. Crabtree, P.C. Scacheri, Y. Ji, E.A. Novotny, L. Garrett-Beal, J.M. Ward, S.K. Libutti, A.H. Richard, A. Cerrato, M.J. Parisi, A.S. Santa Anna, B. Oliver, S.C. Chandrasekharappa, F.S. Collins, A.M. Spiegel, and S.J. Marx, Molecular pathology of the MEN1 gene. Ann N Y Acad Sci, 2004. 1014: p. 189-98.

33. Ellard, S., A.T. Hattersley, C.M. Brewer, and B. Vaidya, Detection of an MEN1 gene mutation depends on clinical features and supports current referral criteria for diagnostic molecular genetic testing. Clin Endocrinol, 2005. 62(2): p. 169-75.

34. Crabtree, J.S., P.C. Scacheri, J.M. Ward, L. Garrett-Beal, M.R. Emmert-Buck, K.A. Edgemon, D. Lorang, L. S.K., S.C. Shandrasekharappa, S.J. Marx, A.M. Spiegel, and F.S. Collins, A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. PNAS, 2001. 98(3): p. 1118-23.

35. Cavallari, I., D.M. D'Agostini, T. Ferro, A. Rosato, L. Barzon, C. Pasquali, P. Fogar, M. Theodoropoulou, G. Esposito, M. Boscaro, U. Pagotto, E. Tebaldi, F. Fallo, L. Chieco-Bianchi, and V. Ciminale, In situ analysis of human menin in normal and neoplastic pancreatic tissues: evidence for differential expression in exocrine and endocrine cells. J Clin Endocrinol Metab, 2003. 88(8): p. 3898-901.

36. Agarwal, S.K., S.C. Guru, C. Heppner, M.R. Erdos, R.M. Collins, S.Y. Park, S. Saggar, S.C. Chandrasekharappa, F.S. Collins, A.M. Spiegel, S.J. Marx, and A.L. Burns, Menin interacts with the AP1 transcriptin factor JunD and represses JunD-activated transcription. Cell, 1999. 96: p. 143-52.

37. La, P., A.C. Silva, Z. Hou, H. Wang, R.W. Schnepp, N. Yan, Y. Shi, and X. Hua, Direct binding of DNA by tumor suppressor menin. J Biol Chem, 2004. 279(47): p. 49045-54.

38. Schnepp, R.W., Z. Hou, H. Wang, C. Petersen, A.C. Silva, H. Masai, and X. Hua, Functional interaction between tumor supressor menin and activator of S-phase kinase. Cancer Res, 2004. 64(18): p. 6791-6.

39. Milne, T.A., C.M. Hughes, R.V. Lloyd, Z. Yang, O. Rozenblatt-Rosen, Y. Dou, R.W. Schnepp, C. Krankel, V.A. Livolsi, D. Gibbs, X. Hua, R.G. Roeder, M. Meyerson, and J.L. Hess, Menin and MLL cooperatively regulate expression of cyclin-dependent kinase inhibitors. Proc Natl Acad Sci U S A, 2005. 102(3): p. 749-54.

40. Poisson, A., B. Zablewska, and P. Gaudray, Menin interacting proteins as clues toward the understanding of multiple endocrine neoplasia type 1. Cancer Lett, 2003. 189(1): p. 1-10.

41. Goebel, S.U., C. Heppner, A.L. Burns, S.J. Marx, A.M. Spiegel, Z. Zhuang, I.A. Lubensky, F. Gibril, R.T. Jensen, and J. Serrano, Genotype/Phenotype correlation of multiple endocrine neoplasia type 1 agene mutations in sporadic gastrinomas. J Clin Endocrinol Metab, 2000. 85: p. 116-23.

42. Zhuang, Z., A. Vortmeyer, S. Pack, S. Huang, T.A. Pham, C. Wang, W.S. Park, S.K. Agarwal, L.V. Debelenko, M.B. Kester, S.C. Guru, P. Manickam, S.E. Olufemi, F. Yu, C. Heppner, J.S. Crabtree, M.C. Skarulis, D.J. Venzon, M.R. Emmert-Buck, A.M. Spiegel, S.C. Chandrasekharappa, F.S. Collins, A.L. Burns, S.J. Marx, R.T. Jensen, L.A. Liotta, and I.A. Lubensky, Somatic mutations in the MEN1 sumor suppressor gene in sporadic gastrinomas and insulinomas. Cancer Res, 1997. 58: p. 4417-20.

43. Wang, E.H., S.A. Ebrahimi, A.Y. Wu, C. Kashefi, E. Passaro, Jr., and M.P. Sawicki, Mutation of the MENIN gene in sporadic pancreatic endocrine tumors. Cancer Res, 1998. 58(19): p. 4417-20.

44. Marx, S.J., K. Sakaguchi, J.I. Green, G.D. Aurbach, and M.L. Brandi, Multiple endocrine neoplasia type I: assessment of laboratory tests to screen for the gene in a large kindred. Medicine, 1986. 65: p. 226.

45. Larimore, T.C., L.D. Piersall, M.K. DeBenedetti, W.G. Dilley, M.G. Mutch, A.J. Whelan, and B. Zehnbauer, Clinical genetic testing and early surgical intervention in patients with multiple endocrine neoplasia type 1 (MEN1). Ann Surg, 2004. 239(5): p. 645-7.

46. Wilkinson, S. and B.T. Teh, Cause of death in multiple endocrine neoplasia type I. Arch Surg, 1993. 128: p. 683.

47. Thompson, N.W., Current concepts in the surgical management of multiple endocrine neoplasia type 1 pancreatic-duodenal disease. Results in the treatment of 40 patients with Zollinger-Ellison syndrome, hypoglycaemia or both. J Intern Med, 1998. 243(6): p. 495-500.

48. Gauger, P.G., J.M. Scheiman, E.J. Wamsteker, M.L. Richards, G.M. Doherty, and N.W. Thompson, Role of endoscopic ultrasonography in screening and treatment of pancreatic endocrine tumors in asymptomatic patients with multiple endocrine neoplasia type 1. Br J Surg, 2003. 90(6): p. 748-54.

49. Langer, P., P.H. Kann, V. Fendrich, G. Richter, S. Diehl, M. Rothmund, and D.K. Bartsch, Prospective evaluation of imaging procedures for the detection of pancreaticoduodenal endocrine tumors in patients with multiple endocrine neoplasia type 1. World J Surg, 2004. 28(12): p. 1317-22.

50. Yim, J.H., B.A. Siegel, M.K. DeBenedetti, J.A. Norton, T.C. Lairmore, and G.M. Doherty, Prospective study of the utility of somatostatin-receptor scintigraphy in the evaluation of patients with multiple endocrine neoplasia type 1. Surgery, 1998. 124(6): p. 1037-42.

51. Doherty, G.M., T.C. Lairmore, and M.K. DeBenedetti, Multiple endocrine neoplasia type 1 parathyroid adenoma development over time. World J Surg, 2004. 28(11): p. 1139-42.

52. Shepherd, J.J., J.R. Burgess, T.M. Greenaway, and R. Ware, Preoperative sestamibi scanning and surgical findings at bilateral, unilateral, or minimal reoperation for recurrent hyperparathyroidism after subtotal parathyroidectomy in patients with multiple endocrine neoplasia type 1. Arch Surg, 2000. 135(7): p. 844-8.

53. Lafferty, F.W., Primary hyperparathyroidism: changing clinical spectrum, prevalence of hypertension and discriminant analysis of laboratory tests. Arch Intern Med, 1981. 141: p. 1761.

54. Tonelli, F., S. Spini, M. Tommasi, G. Gabbrielli, A. Amorosi, A. Brocchi, and M.L. Brandi, Intraoperative parathormone measurement in patients with multiple endocrine neoplasia type I syndrome and hyperparathyroidism. World J Surg, 2000. 24(5): p. 556-62; discussion 562-3.

55. Arnalsteen, L.C., P.F. Alesina, J.L. Quiereux, S.G. Farrel, F.N. Patton, B.M. Carnaille, C.M. Cardot-Bauters, J.L. Wemeau, and C.A. Proye, Long-term results of less than total parathyroidectomy for hyperparathyroidism in multiple endocrine neoplasia type 1. Surgery, 2002. 132(6): p. 1119-24.

56. Lambert, L.A., S.E. Shapiro, J.E. Lee, N.D. Perrier, M. Truong, M.J. Wallace, A.O. Hoff, R.F. Gagel, and D.B. Evans, Surgical treatment of hyperparathyroidism in patients with multiple endocrine neoplasia type 1. Arch Surg, 2005. 140(4): p. 374-82.

57. Prinz, R.A., O.I. Gamvros, and D. Sellu, Subtotal parathyroidectomy for primary chief cell hyperplasia of the multiple endocrine neoplasia type I syndrome. Ann Surg, 1981. 193: p. 26.

58. Wells, S.A., Jr., D.J. Gunnells, et al., The successful transplantation of frozen parathyroid in man. Surgery, 1977. 81: p. 86.

59. Hellman, P., B. Skogseid, K. Oberg, C. Juhlin, G. Akerstrom, and J. Rastad, Primary and reoperative parathyroid operations in hyperparathyroidism of multiple endocrine neoplasia type 1. Surgery, 1998. 124(6): p. 993-9.

60. Vassilopoulou, R. and J. Ajani, Islet cell tumors of the pancreas. Endocrinol Metab Clin North Am, 1994. 23: p. 53.

61. Norton, J.A., J.L. Doppman, and R.T. Jensen, Curative resection in Zollinger-Ellison sydrome. Ann Surg, 1992. 215: p. 8.

62. Thom, A.K. and J.A. Norton, Localization, incidence, and malignant potential of duodenal gastrinomas. Surgery, 1992. 110: p. 1086.

63. Norton, J.A. and R.T. Jensen, Resolved and unresolved controversies in the surgical management of patients with Zollinger-Ellison syndrome. Ann Surg, 2004. 240(5): p. 757-73.

64. Cadiot, G., A. Vuagnat, I. Doukhan, A. Murat, G. Bonnaud, B. Delemer, G. Thiefin, A. Beckers, M. Veyrac, C. Proye, P. Ruszniewski, and M. Mignon, Prognostic factors in patients with Zollinger-Ellison syndrome and multiple endocrine neoplasia type 1. Groupe d'Etude des Neoplasies Endocriniennes Multiples (GENEM and groupe de Recherche et d'Etude du Syndrome de Zollinger-Ellison (GRESZE). Gastroenterology, 1999. 116(2): p. 286-93.

65. Lowney, J.K., M.M. Frisella, T.C. Lairmore, and G.M. Doherty, Pancreatic islet cell tumor metastasis in multiple endocrine neoplasia type 1: correlation with primary tumor size. Surgery, 1998. 124(6): p. 1043-8, discussion 1048-9.

66. Thompson, N.W., A.G. Bondeson, L. Bondeson, and A.I. Vinik, The surgical treatment of gastrinoma in MEN I syndrome patients. Surgery, 1989. 106: p. 1081.

67. Norton, J., H. Alexander, D. Fraker, V. DJ, F. Gibril, and J. RT, Comparison of Surgical Results in Patients With Advanced and Limited Disease With Multiple Endocrine Neoplasia Type I and Zollinger-Ellison Syndrome. Annals of Surgery, 2001. 234(4): p. 495-506.

68. Maton, P.N., J.D. Gardner, and R.T. Jensen, Diagnosis and management of Zollinger-Ellison syndrome. Endocrinol Metab Clin North Am, 1989. 18: p. 519.

69. Verges, B., F. Boureille, P. Goudet, A. Murat, A. Beckers, G. Sassolas, P. Cougard, B. Chambe, C. Montvernay, and A. Calender, Pituitary disease in MEN type 1 (MEN 1): data from the France-Belgium MEN1 multicenter study. J Clin Endocrinol Metab, 2002. 87(2): p. 457-65.

70. Ezzat, S. and P.J. Snyder, Octreotide treatment of acromegaly. Ann Intern Med, 1992. 117: p. 711.

71. Ferolla, P., A. Falchetti, P. Filosso, P. Tomassetti, G. Tamburrano, N. Avenia, G. Daddi, F. Puma, R. Ribacchi, F. Santeusanio, G. Angeletti, and M.L. Brandi, Thymic neuroendocrine carcinoma (carcinoid) in multiple endocrine neoplasia type 1 syndrome: the Italian series. J Clin Endocrinol Metab, 2005. 90(5): p. 2603-9.

72. Gibril, F., Y.J. Chen, D.S. Schrump, A. Vortmeyer, Z. Zhuang, I.A. Lubensky, J.C. Reynolds, A. Louie, L.K. Entsuah, K. Huang, B. Asgharian, and R.T. Jensen, Prospective study of thymic carcinoids in patients with multiple endocrine neoplasia type 1. J Clin Endocrinol Metab, 2003. 88(3): p. 1066-81.

73. Sachithanandan, N., R.A. Harle, and J.R. Burgess, Broncopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer, 2005. 103(3): p. 509-15.

74. Norton, J.A., M.L. Melcher, F. Gibril, and R.T. Jensen, Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. Surgery, 2004. 136(6): p. 1267-74.

75. Nehar, D., C. Lombard-Bohas, S. Olivieri, B. Claustrat, J.A. Chayvialle, M.C. Penes, G. Sassolas, and F. Borson-Chazot, Interest of Chromogranin A for diagnosis and follow-up of endocrine tumors. Clin Endocrinol, 2004. 60(5): p. 644-52.

76. Jensen, R.T., Management of the Zollinger-Ellison syndrome in patients with multiple endocrine neoplasia type 1. J Intern Med, 1998. 243(6): p. 477-88.

77. Dean, P.G., J.A. van Heerden, D.R. Farley, G.B. Thompson, C.S. Grant, W.S. Harmsen, and D.M. Ilstrup, Are patients with multiple endocrine neoplasia type I prone to premature death? World J Surg, 2000. 24(11): p. 1437-41.

78. Doherty, G.M., J.A. Olson, M.M. Frisella, T.C. Lairmore, S.A. Wells, Jr., and J.A. Norton, Lethality of multiple endocrine neoplasia type I. World J Surg, 1998. 22(6): p. 581-6; discussion 586-7.

79. Easton, D.F. and M.A. Ponder, The clinical and screening age-at-onset distribution for the MEN 2 syndrome. Am J Hum Genet, 1989. 44: p. 208.

80. Hartmut, P.H., M.D. Neumann, and P. Dietmar, Pheochromocytomas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. N Engl J Med, 1994. 329: p. 153.

81. Raue, F. and K. Frank-Raue, Multiple endocrine neoplasia type 2: clinical features and screening. Endocrinol Metab Clin North Am, 1994. 23: p. 137.

82. Cohen, M.S., J.E. Phay, C. Albinson, M.K. DeBenedetti, M.A. Skinner, T.C. Lairmore, G.M. Doherty, D.M. Balfe, S.A. Wells, Jr., and J.F. Moley, Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg, 2002. 235(5): p. 648-54.

83. Kahiri, M., R.N. Dexter, N.J. Burzynski, and C.C. Johnston Jr., Mucosal neuroma, pheochromocytoma, and medullary thyroid carcinoma. MEN type III. Medicine, 1975. 54: p. 89.

84. Williams, E.D. and D.J. Pollock, Multiple mucosal neuromata with endocrine tumors: a syndrome allied to Von Recklinghausen's disease. J Pathol Bacteriol, 1966. 91: p. 71.

85. Grobmyer, S.R., J.G. Guillem, D.S. O'Riordain, J.M. Woodruff, C. Shriver, and M.F. Brennan, Colonic manifestations of multiple endocrine neoplasia type 2B: report of four cases. Dis Colon Rectum, 1999. 42(9): p. 1216-9.

86. Farndon, J.R., G.S. Leight, W.G. Dilley, et al., Familial medullary thyroid carcinoma without associated endocrinopathies: a distinct clinical entity. Br J Surg, 1986. 73: p. 278.

87. Baylin, S.B. and G. Mendelsohn, Tumor Cell Heterogeneity, Origins and Implications. Medullary thyroid carcinoma: a model for the study of human tumor progression and cell heterogeneity., ed. A.H. Owens Jr., D.S. Coffey, and S.B. Baylin. 1982, New York: Academic Press. 1.

88. Gagel, R.F., A.H. Tashjian, T. Cummings, et al., The clinical outcome of prospective screening for multiple endocrine neoplasia type 2a. N Engl J Med, 1988. 318: p. 478.

89. Airaksinen, M.S., A. Titievsky, and M. Saarma, GDNF family neurotrophic factor signaling: four masters, one servant? Mol Cell Neurosci, 1999. 13(5): p. 313-25.

90. Noll, W.W., Utility of RET mutation analysis in multiple endocrine neoplasia type 2. Arch Pathol Lab Med, 1999. 123(11): p. 1047-9.

91. Eng, C., RET proto-oncogene in the development of human cancer. J Clin Oncol, 1999. 17(1): p. 380-93.

92. Acton, D.S., D. Velthuyzen, C.J. Lips, and J.W. Hoppener, Multiple endocrine neoplasia type 2B mutation in human RET oncogene induces medullary thyroid carcinoma in transgenic mice. Oncogene, 2000. 19(27): p. 3121-5.

93. Ponder, B.A., The phenotypes associated with ret mutations in the multiple endocrine neoplasia type 2 syndrome. Cancer Res, 1999. 59(7 Suppl): p. 1736s-1741s; discussion 1742s.

94. Yip, L., G.J. Cote, S.E. Shapiro, G.D. Ayers, C.E. Herzog, R.V. Sellin, S.I. Sherman, R.F. Gagel, J.E. Lee, and D.B. Evans, Multiple endocrine neoplasia type 2: evaluation of the genotype-phenotype relationship. Arch Surg, 2003. 138(4): p. 109-16.

95. Punales, M.K., H. Graf, J.L. Gross, and A.L. Maia, RET codon 634 mutations in multiple endocrine neoplasia type 2: variable clinical features and clinical outcome. J Clin Endocrinol Metab, 2003. 88(6): p. 2644-9.

96. Jain, S., M.A. Watson, M.K. DeBenedetti, Y. Hiraki, J.F. Moley, and J. Milbrandt, Expression profiles provide insights into early malignant potential and skeletal abnormalities in multiple endocrine neoplasia type 2B syndrome tumors. Cancer Res, 2004. 64(11): p. 3907-13.

97. Norton, J.A., L.J. Froome, R.E. Farell, and S.A. Wells, Jr., Multiple endocrine neoplasia type IIb: the most aggressive form of medullary thyroid cancer. Surg Clin North Am, 1979. 59: p. 109.

98. Kaufman, F.R., T.F. Roe, H.J. Isaacs, and J.J. Weitzmann, Metastatic medullary thyroid carcinoma in young children with mucosal neuroma syndrome. Pediatrics, 1982. 70: p. 263.

99. Nguyen, L., P. Niccoli-Sire, P. Caron, D. Bastie, B. Maes, G. Chabrier, O. Chabre, V. Rohmer, P. Lecomte, J.F. Henry, and B. Conte-Devois, Phoechromocytoma in the multiple endocrine neoplaia type 2: a prospective study. European Journal of Endocrinology, 2000. 144: p. 37-44.

100. van Heerden, J.A., C.F. Roland, A. Carney, S.G. Sheps, and C.S. Grant, Long-term evaluation following resection of apparently benign pheochromocytoma(s)/paranglioma(s). World J Surg, 1990. 14: p. 325.

101. Keiser, H.R., Doppman. J.L., C.N. Robertson, W.M. Linehan, and S. Averbuch, Pathology of the Adrenal Glands. Diagnosis, localization, and management of pheochromocytoma., ed. E.E. Lack. 1990, New York: Churchill Livingstone. 1.

102. Shapiro, B. and L.M. Fig, Management of pheochromocytoma. Endocrinol Metab Clin North Am, 1989. 18: p. 443.

103. Bonnin, F. and M. Schlumberger, Screening for adrenal medullary disease in patients with medullary thyroid carcinoma. J Endocrinol Invest, 1994. 17: p. 253.

104. Cornelis, J.M. and M.D. Lips, Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasis type 2a. N Engl J Med, 1994. 331: p. 828.

105. McMahon, R. and L.M. Mulligan, Direct, non-radioactive detection of mutations in multiple endocrine neoplasia type 2a families. Hum Mol Genet, 1994. 3: p. 643.

106. O'Riordain, D.S. and T. O'Brain, Surgical management of primary hyperparathyroidism in multiple neoplasisa type 1 and 2. Surgery, 1993. 114: p. 1031.

107. Wells, S.A., Jr. and D.D. Chi, Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2a. Ann Surg, 1994. 220: p. 237.

108. Eisenhofer, G., J.W. Lenders, W.M. Linehan, M.M. Walther, D.S. Goldstein, and H.R. Keiser, Plasma normetanephrine and metanephrine for detecting pheochromocytoma in von Hippel-Lindau disease and multiple endocrine neoplasia type 2. N Engl J Med, 1999. 340(24): p. 1872-9.

109. Wells, S.A., Jr., W.G. Dilley, J.A. Farndon, G.S. Leight, and S.B. Baylin, Early diagnosis and treatment of medullary thyroid carcinoma. Arch Intern Med, 1985. 145: p. 1248.

110. Snow, K.J. and A.E.I. Boyd, Management of individual tumor syndromes, medullary thyroid carcinoma and hyperthyroidism. Endocrinol Metab Clin North Am, 1994. 23: p. 157.

111. Yip, L., J.E. Lee, S.E. Shapiro, S.G. Waguespack, S.I. Sherman, A.O. Hoff, R.F. Gagel, J.F. Arens, and D.B. Evans, Surgical management of hereditary pheochromocytoma. J Am Coll Surg, 2004. 198(4): p. 525-34.

112. Delius, R.E. and N.W. Thompson, Early total thyroidectomy in patients with multiple endocrine neoplasia IIb syndrome. Surg Gynecol Obstet, 1989. 169: p. 442.

113. Harness, J.K., L. Fung, N.W. Thompson, R.E. Burney, and M.K. McLeod, Total thyroidectomy: complications and technique. World J Surg, 1986. 10: p. 781.

114. Russell, C.F., van Heerden, J.A., G.W. Sizemore, et. al., The surgical management of medullary thyroid carcinoma. Ann Surg, 1983. 197: p. 42.

115. Wells, S.A., Jr. and C. Franz, Medullary carcinoma of the thyroid gland. World J Surg, 2000. 24(8): p. 952-6.

116. Gimm, O., J. Ukkat, B.E. Niederle, T. Weber, P.N. Thanh, M. Brauckhoff, N. B., and H. Dralle, Timing and extent of surgery in patients with familial medullary thyroid carcinoma/multiple endocrine neoplasia 2A-related RET mutations not affecting codon 634. World J Surg, 2004. 28(12): p. 1312-6.

117. Machens, A., P. Niccoli-Sire, J. Hoegel, K. Frank-Raue, T.J. van Vroonhoven, H.D. Roeher, R.A. Wahl, P. Lamesch, F. Raue, B. Conte-Devolx, and H. Dralle, Early Malignant Progression of Hereditary Medullary Thyroid Cancer. N Engl J Med, 2003. 349(16): p. 1517-1525.

118. Mallette, L.E., Management of hyperparathyroidism in the multiple endocrine neoplasia syndromes and other familial endocrinopathies. Endocrinol Metab Clin North Am, 1994. 23: p. 19.

119. Kebebew, E., P.H. Ituarte, A.E. Siperstein, Q.Y. Duh, and O.H. Clark, Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer, 2000. 88(5): p. 1139-48.

120. Cohen, R., J.M. Campos, C. Salaun, H.M. Heshmati, J.L. Kraimps, C. Proye, E. Sarfati, J.F. Henry, P. Niccoli-Sire, and E. Modigliani, Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). J Clin Endocrinol Metab, 2000. 85(2): p. 919-22.

121. Tung, W.S., T.M. Vesley, and J.F. Moley, Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery, 1995. 118: p. 1024-30.

122. Moley, J.F., W.G. Dilley, and M.K. DeBenedetti, Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg, 1997. 225(6): p. 734-40; discussion 740-3.

123. Samaan, N.A., P.N. Schultz, and R.C. Hickey, Medullary thyroid carcinoma: prognosis of familial versus sporadic disease and the role of radiotherapy. J Clin Endocrinol Metab, 1988. 67: p. 801.

124. Averbuch, S., L. Wu, D. Pertsemlidis, and T. Drakes, Cyclophosphamide (C), vincristine (V), and dacarbazine (D) for advanced neuroendocrine carcinomas. Proc Am Soc Clin Oncol, 1990. 9: p. 382.

125. Petursson, S.R., Metastatic medullary thyroid carcinoma: complete response to combination chemotherapy with dacarbazine and 5-fluorouracil. Cancer, 1988. 62: p. 1899.

126. Shimaoka, K., D.A. Schoenfeld, W. DeWys, R.H. Creech, and R. DeConti, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer, 1984. 56: p. 2155.

127. Wu, L.-T. and S.D. Averbuch, Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine. Cancer, 1994. 73: p. 432.